Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Why people in the “community” avoid the word well-being|柏原里美|編集者・ファシリテーター

    November 21, 2026

    How Standardized Workers’ Comp Forms Help HR Teams (2026)

    November 21, 2026

    First Human Trial to Slash Bad Cholesterol by 50% With One Injection of CRISPR Gene-Editing Therapy

    November 21, 2026
    Facebook X (Twitter) Instagram
    Trending
    • Why people in the “community” avoid the word well-being|柏原里美|編集者・ファシリテーター
    • How Standardized Workers’ Comp Forms Help HR Teams (2026)
    • First Human Trial to Slash Bad Cholesterol by 50% With One Injection of CRISPR Gene-Editing Therapy
    • Pub Owner Spends Thousands on Stunning Holiday Display–All to Cheer Up Depressed Locals
    • 7 Evening Habits That Can Make You More Productive Tomorrow
    • The Challenges Facing Men That T…
    • Beyond Physical Wellness: How Health Insurance Is Making Mental Health Care More Accessible in India
    • Team Building Activities for Work: 15 Ideas That Work
    Moving MountainsMoving Mountains
    Facebook X (Twitter) Instagram
    Saturday, November 21
    • Home
    • Mental Health
    • Life Skills
    • Self-Care
    • Well-Being
    • Awareness
    • Inspiration
    • Workers Comp
    • Social Security
      • Injuries
      • Disability Support
      • Community
    Moving MountainsMoving Mountains
    Home » First Human Trial to Slash Bad Cholesterol by 50% With One Injection of CRISPR Gene-Editing Therapy
    Community

    First Human Trial to Slash Bad Cholesterol by 50% With One Injection of CRISPR Gene-Editing Therapy

    TECHBy TECHNovember 21, 2026No Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Reddit WhatsApp Email
    First Human Trial to Slash Bad Cholesterol by 50% With One Injection of CRISPR Gene-Editing Therapy
    Share
    Facebook Twitter LinkedIn Pinterest WhatsApp Email

    Credit: Sangharsh Lohakare

    A one-time infusion of CRISPR gene editing therapy slashed dangerous cholesterol by 52%, with the patients still experiencing the benefit 12 months after initial treatment, and without side effects.

    The Cleveland Clinic in Ohio reported that their Phase 1 human trial showed a one-time infusion of a gene-editing therapy using CRISPR-Cas9 was effective and safe in reducing “bad” LDL cholesterol and triglycerides by nearly half in patients throughout a one-year follow-up, after their disorder had previously been resistant to medication.

    The trial, which included 15 patients, aimed to see if the reductions in LDL cholesterol and triglycerides previously reported after two months would persist for 12 months. After 12 months, patients who were treated with the highest dose saw a 52.5% lowering from baseline in LDL cholesterol, and a 47.8% reduction in triglycerides. There were no serious adverse events related to the therapy during the one-year follow-up.

    The study, published in the New England Journal of Medicine in August, was funded by CRISPR Therapeutics AG in Switzerland.

    “The durability of the lipid-lowering effect was impressive,” said Cleveland Clinic cardiologist Dr. Luke Laffin, the first author of the study.

    “It is encouraging that there were no serious safety events related to CTX310 in the trial and in the year following treatment. We look forward to continuing to investigate this therapy in a larger number of patients.”

    CRISPR-Cas9 is a gene-editing technology that can be used to modify or correct specific regions of a person’s DNA to treat serious diseases.

    This trial tested CTX310, an experimental CRISPR-Cas9 gene-editing treatment that is delivered as a one-time infusion. CTX310 carries the CRISPR editing mechanism into the liver, where it switches off a gene called ANGPTL3. Turning off this gene can lower LDL cholesterol and triglycerides, which are both linked to heart disease.

    CHEESE LOVERS NOTE: The Benefits of Full-Fat Dairy Documented in Study Without Cholesterol Rise or Weight Gain

    During the trial, CTX310 was administered at doses from 0.1 to 0.8 mg/kg during the single infusion, after pre-treatment with corticosteroids and antihistamines. Participants were monitored for safety of the treatment, and the effects of this gene therapy on ANGPTL3, LDL cholesterol and triglyceride levels. CTX310 reduced both LDL cholesterol and triglycerides by approximately 50% on average at the highest dose 12 months after the treatment.

    The study participants were monitored for one year following the trial, with additional long-term safety follow-up planned for the next 15 years, as recommended by the FDA for all gene-editing therapies.

    Additionally, the results of a related study were presented last week at the American Heart Association’s annual meeting in Chicago, showing the CTX310 therapy slashed dangerous triglyceride levels by 63%–85% in 10 adults with severe hyper-triglyceridemia—and it only took 30 days after receiving a single injection.

    SHARE THE EXCITING NEWS With Family On Social Media…

    Bad Cholesterol CRISPR GeneEditing human Injection Slash Therapy trial
    TECH
    • Website

    Related Posts

    33 Kids Wrote Letters to a Wounded Veteran. 50 Years Later, His Son Is Searching to Thank Each One

    November 20, 2026

    Every Tuesday, This Chef Cooks for 100 People in Need Using Random Food Bank Ingredients

    November 20, 2026

    Rhino Dung Paper Is How This Family Makes Money and Protects These Amazing Animals

    November 20, 2026
    Leave A Reply Cancel Reply

    Don't Miss
    Well-Being

    Why people in the “community” avoid the word well-being|柏原里美|編集者・ファシリテーター

    By TECHNovember 21, 20260

    Why people in the “community” avoid the word well-beingI am a Yamabushi, a journaling guide,…

    How Standardized Workers’ Comp Forms Help HR Teams (2026)

    November 21, 2026

    First Human Trial to Slash Bad Cholesterol by 50% With One Injection of CRISPR Gene-Editing Therapy

    November 21, 2026

    Pub Owner Spends Thousands on Stunning Holiday Display–All to Cheer Up Depressed Locals

    November 21, 2026
    Stay In Touch
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    Our Picks

    Why people in the “community” avoid the word well-being|柏原里美|編集者・ファシリテーター

    November 21, 2026

    How Standardized Workers’ Comp Forms Help HR Teams (2026)

    November 21, 2026

    First Human Trial to Slash Bad Cholesterol by 50% With One Injection of CRISPR Gene-Editing Therapy

    November 21, 2026

    Pub Owner Spends Thousands on Stunning Holiday Display–All to Cheer Up Depressed Locals

    November 21, 2026

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    About Us

    At Moving Mountains, we believe that every individual has strength, value, and purpose—regardless of mental health challenges or physical disabilities. This platform was created to inspire hope, promote understanding, and empower people to live meaningful and confident lives beyond limitations.

    Latest Post

    Why people in the “community” avoid the word well-being|柏原里美|編集者・ファシリテーター

    November 21, 2026

    How Standardized Workers’ Comp Forms Help HR Teams (2026)

    November 21, 2026

    First Human Trial to Slash Bad Cholesterol by 50% With One Injection of CRISPR Gene-Editing Therapy

    November 21, 2026
    Recent Posts
    • Why people in the “community” avoid the word well-being|柏原里美|編集者・ファシリテーター
    • How Standardized Workers’ Comp Forms Help HR Teams (2026)
    • First Human Trial to Slash Bad Cholesterol by 50% With One Injection of CRISPR Gene-Editing Therapy
    • Pub Owner Spends Thousands on Stunning Holiday Display–All to Cheer Up Depressed Locals
    • 7 Evening Habits That Can Make You More Productive Tomorrow
    Facebook X (Twitter) Instagram Pinterest
    • About Us
    • Contact Us
    • Privacy Policy
    • Terms & Conditions
    • Disclaimer
    © 2026 movingmountains. Designed by Pro.

    Type above and press Enter to search. Press Esc to cancel.